PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE
An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically accep...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | ABRAHAMSSON, BERTIL, SVEN, INGE HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER BAGGER-JOERGENSEN, HAAKAN, LARS CULLBERG, MARIE, CHRISTINE, SINDEBY ABRAHMSEN ALAMI, SUSANNA, JOHANNA NILSSON, SUSANNE, ANETTE |
| description | An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.
L'invention concerne une formulation pharmaceutique à libération prolongée qui comprend comme principe actif le composé Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ou un sel pharmaceutiquement acceptable de ce composé (p. ex. sel d'acide sulfonique tel que le sel d'acide benzène sulfonique (bésylate)); et un diluant ou un excipient pharmaceutiquement acceptable; ladite formulation est destinée à produire un effet antithrombotique tout en limitant les interactions médicament-médicament avec un ou plusieurs autres médicament(s) administré(s) de manière concomitante, en particulier ceux qui sont métabolisés par les enzymes CYP-450. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_WO2009027745A1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>WO2009027745A1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_WO2009027745A13</originalsourceid><addsrcrecordid>eNrjZNAP8HAM8nV0dg0N8XR29FFw8w_yDfVxDPH09wOxFVwjQlz9XFxdFIJcfVwdg115GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYGlgZG5uYmpo6ExcaoAtHMnGg</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE</title><source>esp@cenet</source><creator>ABRAHAMSSON, BERTIL, SVEN, INGE ; HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER ; BAGGER-JOERGENSEN, HAAKAN, LARS ; CULLBERG, MARIE, CHRISTINE, SINDEBY ; ABRAHMSEN ALAMI, SUSANNA, JOHANNA ; NILSSON, SUSANNE, ANETTE</creator><creatorcontrib>ABRAHAMSSON, BERTIL, SVEN, INGE ; HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER ; BAGGER-JOERGENSEN, HAAKAN, LARS ; CULLBERG, MARIE, CHRISTINE, SINDEBY ; ABRAHMSEN ALAMI, SUSANNA, JOHANNA ; NILSSON, SUSANNE, ANETTE</creatorcontrib><description>An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.
L'invention concerne une formulation pharmaceutique à libération prolongée qui comprend comme principe actif le composé Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ou un sel pharmaceutiquement acceptable de ce composé (p. ex. sel d'acide sulfonique tel que le sel d'acide benzène sulfonique (bésylate)); et un diluant ou un excipient pharmaceutiquement acceptable; ladite formulation est destinée à produire un effet antithrombotique tout en limitant les interactions médicament-médicament avec un ou plusieurs autres médicament(s) administré(s) de manière concomitante, en particulier ceux qui sont métabolisés par les enzymes CYP-450.</description><language>eng ; fre</language><subject>HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><creationdate>2009</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090305&DB=EPODOC&CC=WO&NR=2009027745A1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20090305&DB=EPODOC&CC=WO&NR=2009027745A1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>ABRAHAMSSON, BERTIL, SVEN, INGE</creatorcontrib><creatorcontrib>HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER</creatorcontrib><creatorcontrib>BAGGER-JOERGENSEN, HAAKAN, LARS</creatorcontrib><creatorcontrib>CULLBERG, MARIE, CHRISTINE, SINDEBY</creatorcontrib><creatorcontrib>ABRAHMSEN ALAMI, SUSANNA, JOHANNA</creatorcontrib><creatorcontrib>NILSSON, SUSANNE, ANETTE</creatorcontrib><title>PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE</title><description>An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.
L'invention concerne une formulation pharmaceutique à libération prolongée qui comprend comme principe actif le composé Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ou un sel pharmaceutiquement acceptable de ce composé (p. ex. sel d'acide sulfonique tel que le sel d'acide benzène sulfonique (bésylate)); et un diluant ou un excipient pharmaceutiquement acceptable; ladite formulation est destinée à produire un effet antithrombotique tout en limitant les interactions médicament-médicament avec un ou plusieurs autres médicament(s) administré(s) de manière concomitante, en particulier ceux qui sont métabolisés par les enzymes CYP-450.</description><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2009</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNrjZNAP8HAM8nV0dg0N8XR29FFw8w_yDfVxDPH09wOxFVwjQlz9XFxdFIJcfVwdg115GFjTEnOKU3mhNDeDsptriLOHbmpBfnxqcUFicmpeakl8uL-RgYGlgZG5uYmpo6ExcaoAtHMnGg</recordid><startdate>20090305</startdate><enddate>20090305</enddate><creator>ABRAHAMSSON, BERTIL, SVEN, INGE</creator><creator>HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER</creator><creator>BAGGER-JOERGENSEN, HAAKAN, LARS</creator><creator>CULLBERG, MARIE, CHRISTINE, SINDEBY</creator><creator>ABRAHMSEN ALAMI, SUSANNA, JOHANNA</creator><creator>NILSSON, SUSANNE, ANETTE</creator><scope>EVB</scope></search><sort><creationdate>20090305</creationdate><title>PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE</title><author>ABRAHAMSSON, BERTIL, SVEN, INGE ; HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER ; BAGGER-JOERGENSEN, HAAKAN, LARS ; CULLBERG, MARIE, CHRISTINE, SINDEBY ; ABRAHMSEN ALAMI, SUSANNA, JOHANNA ; NILSSON, SUSANNE, ANETTE</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_WO2009027745A13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre</language><creationdate>2009</creationdate><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><toplevel>online_resources</toplevel><creatorcontrib>ABRAHAMSSON, BERTIL, SVEN, INGE</creatorcontrib><creatorcontrib>HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER</creatorcontrib><creatorcontrib>BAGGER-JOERGENSEN, HAAKAN, LARS</creatorcontrib><creatorcontrib>CULLBERG, MARIE, CHRISTINE, SINDEBY</creatorcontrib><creatorcontrib>ABRAHMSEN ALAMI, SUSANNA, JOHANNA</creatorcontrib><creatorcontrib>NILSSON, SUSANNE, ANETTE</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>ABRAHAMSSON, BERTIL, SVEN, INGE</au><au>HJAERTSTAM, LARS, JOHAN, PONTUS DE VERDIER</au><au>BAGGER-JOERGENSEN, HAAKAN, LARS</au><au>CULLBERG, MARIE, CHRISTINE, SINDEBY</au><au>ABRAHMSEN ALAMI, SUSANNA, JOHANNA</au><au>NILSSON, SUSANNE, ANETTE</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE</title><date>2009-03-05</date><risdate>2009</risdate><abstract>An extended release pharmaceutical formulation comprising, as active ingredient, the compound Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe) or a pharmaceutically acceptable salt thereof (such as a sulfonic acid salt, such as the benzenesulfonic acid 5 (besylate) salt); and a pharmaceutically acceptable diluent or carrier; for use in providing a therapeutic anti-thrombotic effect whilst limiting drug-drug interactions with other concomitantly dosed drug/s, particularly those which are metabolised by CYP-450 enzymes.
L'invention concerne une formulation pharmaceutique à libération prolongée qui comprend comme principe actif le composé Ph(3-Cl)(5-OCHF2)-(R)CH(OH)C(O)-(S)Aze-Pab(OMe), ou un sel pharmaceutiquement acceptable de ce composé (p. ex. sel d'acide sulfonique tel que le sel d'acide benzène sulfonique (bésylate)); et un diluant ou un excipient pharmaceutiquement acceptable; ladite formulation est destinée à produire un effet antithrombotique tout en limitant les interactions médicament-médicament avec un ou plusieurs autres médicament(s) administré(s) de manière concomitante, en particulier ceux qui sont métabolisés par les enzymes CYP-450.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre |
| recordid | cdi_epo_espacenet_WO2009027745A1 |
| source | esp@cenet |
| subjects | HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES |
| title | PHARMACEUTICAL FORMULATION FOR EXTENDED RELEASE |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-06T20%3A54%3A50IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=ABRAHAMSSON,%20BERTIL,%20SVEN,%20INGE&rft.date=2009-03-05&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EWO2009027745A1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |